IDELVION Connectsm patient support program
Get IDELVION news that matters to you
Call 1-800-676-4266
Monday–Friday,
8 am to 8 pm ET
With IDELVION, Factor IX stays in their body longer
Among patients under 12, with the longest single-dose half-life of any Factor IX therapy
at 90-93 hours,* IDELVION keeps Factor IX levels high enough to extend protection.
In the IDELVION pediatric pivotal trial, children had a median of 0 spontaneous
bleeds per year when dosed every 7 days.
*Based on a single dose of IDELVION at 50 IU/kg in adults (< 12 years).
† Steady-state is a consistent and uniform amount of factor in the body from continued use.
‡Steady-state mean trough is calculated from all observations at any time points. The average dose for patients receiving prophylaxis for every 7 days was 47 IU/kg.
Consider extended dosing when it's time
High factor IX levels offer powerful bleed protection at the very start. After turning 12, patients may be able to work with their doctor to extend dosing and infuse less—only IDELVION is FDA approved for 14-day dosing in adolescents and adults.
Those 12 and older have the option to extend dosing to 14 days once they are well-controlled on 7-day prophylaxis.
§Once well‑controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
Download our resources below for guidance on all ages
and stages of hemophilia B
Whether you have a young child or a teenager, being a caregiver for someone living with hemophilia B can be challenging. Our Caregiver Guide provides tips and knowledge on what to expect during each phase of childhood.
Are you stepping into a new chapter of your life? Check out our Navigating Independence Guide to help you build new habits and take control of your care as you begin this exciting journey.
Milinda spends less time driving to the hospital and more time with her family.
See the impact IDELVION has had on Milinda’s life.
WATCH HER STORY